Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001425738-18-000004
Filing Date
2018-02-14
Accepted
2018-02-14 18:01:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 atara_13ga2.htm SC 13G/A 46072
  Complete submission text file 0001425738-18-000004.txt   47664
Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

EIN.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Subject) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88393 | Film No.: 18614561
SIC: 2836 Biological Products, (No Diagnostic Substances)